Management Forum Logo

Presented by
Management Forum

Pharmaceutical Development of ATMPs Training Course

This course will provide a comprehensive overview of the regulatory, quality and GMP requirements to consider when developing ATMPs.

★★★★★ "Structured and balanced approach in the order of CTD modules enabled a clear understanding on develo... more (13)"

18-19 June 2024
+ 14-15 October 2024 »

from £1099

Need help?  Enrol or reserve

Course overview

This course has been designed to provide a comprehensive overview of the regulatory, quality and good manufacturing practice (GMP) requirements to consider when developing advanced therapy medicinal products (ATMPs).

Industry expterts will cover the regulatory landscape and the definition and classification of ATMPs and provide practical guidance on how to overcome quality and specific GMP challenges. The differences between GMP for ATMPs and conventional therapies will be discussed, as will the requirements for clinical trials and the preparation of the IMPD. Advice on the specific transportation requirements of these products will also be addressed.

This programme will be of benefit to all those involved with or considering developing an ATMP.

Benefits of attending:

  • Understand the GMP requirements for clinical trials in US and Europe
  • Gain a practical insight into other markets
  • Determine critical quality attributes
  • Develop a successful QC strategy
  • Examine the major differences between GMP for ATMPs and conventional therapies
  • Overcome potential pitfalls when manufacturing cells
  • Discuss multi-manufacturing sites for autologous products
  • Consider stability issues
  • Examine risk analysis for biological materials and understand Annex 16
  • Gain an introduction to GMO approval requirements

This seminar will be of benefit to all those involved with or considering developing an Advance Medicinal Therapeutic Product.

This course is part of our GxP training (Good x Practice) course collection, which features a variety of topic areas to ensure you comply with the most recent quality guidelines. For more information on the latest EU GMP regulations, see our GMP training course covering the Annex 1.

Who should attend?

  • R&D personnel involved in research on cell or gene-based therapies
  • Managers involved in the development and manufacture of ATMPs
  • Quality assurance and quality control personnel responsible for quality aspects of ATMPs
  • GMP managers responsible for implementing GMP in ATMP manufacture
  • Regulatory personnel involved in inspections of ATMPs

Enrol or reserve

The Pharmaceutical Development of ATMPs course will cover:

Introduction to ATMPs

  • Definition of ATMPs and associated terms
  • Classification of ATMPs

The Regulatory Landscape

  • Examining the European regulatory landscape for ATMPs – detailed analysis of existing regulation 1394/2007
  • Considering factors lying outside of the regulation’s scope, e.g. combination products
  • Links to related directives, eg Tissues and Cells Directives (2002/98/EC and 2004/23/EC); Medical Device Directive (93/42/EEC) and forthcoming regulation

Strategic Considerations

  • Opportunities to meet with regulators to maximise approval chances
  • ATMP-specific options in the EU: certification procedure, risk-benefit approach
  • Accelerated access opportunities in EU and US
  • Understanding breakthrough status/PRIME

Insight into Global Regulations and Requirements

  • Examining key markets including Europe, US and Japan
  • Evaluate the regulatory differences between regions to help you build a strategic approval route
  • GMP requirements at Phase I in US and Europe – ramifications for your product

Overcoming Quality Challenges

  • Overview of frequent quality concerns
  • Potency assay development
  • Determining critical quality attributes
  • Developing a successful QC strategy for short-shelf-life product
  • QP release: timing and logistical challenges for ATMPs

Understanding Clinical Trials

  • EU clinical trial requirements
  • The US IND

Risk-Based Approach for ATMPs

  • Examining 3.2.A Adventitious Agents
  • Level of data required EU/US


  • What is required: examine the major differences between GMP for ATMPs and conventional therapies
  • Overcoming potential pitfalls when manufacturing cells
  • Current GMP interpretations
  • Multiple manufacturing sites for autologous products
  • Point-of-care preparation devices

Stability and Logistics

  • Considering stability issues
  • Challenges in transporting cell therapies/cryopreservation
  • Preparation on site

Clinical Trial Considerations

  • Optimising materials for regulatory compliance – vendor qualification
  • Risk analysis for biological materials
  • The comparability concept and its importance in preparing for clinical trials
  • Introduction to GMO approval requirements

Practical Considerations for the IMPD

  • Terms and definitions
  • Guidance on IMPD content for ATMPs
  • Data requirements for first-in-human vs later clinical trials

Enrol or reserve

Andrew Willis
San Salvatore Training Ltd

Andrew Willis is an independent consultant providing expert advice and training on global regulatory solutions and pharmaceutical development. Previously, he worked for Catalent Pharma Solutions as VP Regulatory Affairs & Consulting Services, where he was head of a team of internal and external regulatory affairs consultants.

He qualified as a Chemist from the University of Glamorgan, after which he furthered his understanding of pharmaceutical development, working as a research chemist with Parke Davis. He had 10 years manufacturing and analytical experience prior to entering regulatory affairs as a Senior Executive Officer with responsibility for submission of European MAAs and project management of development programs. He has over 30 years’ pharmaceutical experience with extensive knowledge in the development and manufacture of sterile, solid oral, inhalation, topical and biotech pharmaceutical products. These experiences have allowed knowledge of many biotech products requirements with experiences of growth hormones and multiple cancer treatments, including development and clinical registration of the first genetically modified live bacterium for such treatment.
He has extensive experience of major European and US regulatory projects, in the clinical and marketing authorisation stages, and has significant experience in coordinating and managing meetings with European and US Health Authorities.

More details

NEW higher discounts for multiple bookings - bring your colleagues to make your training budget go further:

  • 30% off the 2nd delegate*
  • 40% off the 3rd delegate*
  • 50% off the 4th delegate*

Please contact us for pricing if you are interested in booking 5 or more delegates

18-19 June 2024

Live online

09:00-16:45 UK (London) (UTC+01)
10:00-17:45 Paris (UTC+02)
04:00-11:45 New York (UTC-04)
Course code 13717

  • GBP 1,299
  • EUR 1,869
  • USD 2,129

View basket 

Not ready to book yet?

for 7 days, no obligation

14-15 October 2024

Live online

09:00-16:45 UK (London) (UTC+01)
10:00-17:45 Paris (UTC+02)
04:00-11:45 New York (UTC-04)
Course code 13928

  • GBP 1,099 1,299
  • EUR 1,589 1,869
  • USD 1,817 2,129

Until 09 Sep

View basket 

Not ready to book yet?

for 7 days, no obligation

* Early booking discounts may not be combined with other discounts or offers. As such, the discounts for 2nd/3rd/4th delegates are based on the full price; and apply only when booking multiple delegates on the same date.

Reviews of IPI's Pharmaceutical Development of ATMPs training course

Structured and balanced approach in the order of CTD modules enabled a clear understanding on development and quality, regulatory expectations.

Jun 20 2023

Ramanathan Srinivasan
Senior Director, Viatris UK

Feb 6 2023

excellent Andrew is very knowledgeable and helped us a lot in clarifying most of the ATMP dev processes which are very complicated to link without a given roadmap of the interlinked events.

Andrea Sirianni
Project Manager, Cell & Gene Therapy (CGT)

Feb 6 2023

Andrew was very knowledgeable, provided clear answers with examples on any question he was asked and I consider his slides a treasure of information that one can continuously refer to in the future.

Panos Papoutsis
Project Manager, Cell & Gene Therapy (CGT)

Jun 20 2023

I enjoyed the speaker, Andrew is clearly very knowledgeable and made a good effort to keep the webinar interactive where he could.

Thomas Leyen
External Manufacturing Manager, Pharming Group NV

Jul 14 2022

This course was very relevant to my current profession and it provided a deeper understanding of the challenges associated with cell-based therapy. I really enjoyed the content and the structure. I also liked how Andrew presented the course for day 1 which set the scene for day 2. Most of the presentations also had references and some extra readings, which I will have to go back and read more about. Despite the heaviness of some of the contents, Andrew was still engaging in his presentation. I felt included in the discussions, and I really enjoyed his way of making the course relevant to each participant.

Eugene Padi
Associate Scientist, Novo Nordisk

Oct 5 2020

I liked Andrew's teaching methods mainly engagement of participant all the way through the course.

Rehab Alnabhan
Miltenyi Biotec B.V. & Co. KG

Oct 5 2020

I am very pleased with the webinar.

Astrid Beck Vestergaard
Quality Assurance, Cytovac

Oct 5 2020

I feel the content was detailed and informative.

Anisa Mohamed
Regulatory Affairs Officer, Welsh Blood Service

Oct 7 2019

I liked the course and have already recommended it to my colleagues. The content was very interesting, a lot was covered, and it was really convenient to read everything again at home and have some kind of "handbook" to look into. Both speakers were excellent and useful and clear answers were always given. They always tried to include all attendees and address their specific working areas during the course, which was really great.

Lisa Grabner
Quality Manager Projects, University of Zurich

Apr 4 2019

Great and really interesting.

Heloise Armand
Quality Director, Genzyme Polyclonals

Apr 4 2019

Very good!

Marie-Charlotte Royer
Quality Engineer, Urgo RID

Apr 4 2019

I think Andrew Willis was very entertaining. and had good answers. Maybe even more examples from real life would be good.

Ida Kjær
QA Professional, Novo Nordisk A/S

Oct 2 2018

Great depth of experience. Well presented, very intense and in-depth material.

Elizabeth Watson
Scientific Writer, Hookipa Biotech

United Kingdom

  • Autolus Ltd
  • Cell & Gene Therapy (CGT)
  • CHI
  • Gammadelta Tx
  • Gilead Sciences International Ltd
  • GSK
  • Janssen Research and Development
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • MeiraGTx
  • Miltenyi Biotec Ltd
  • NDA
  • SARQ Pharma Ltd
  • University of Brighton
  • Viatris UK
  • Welsh Blood Service


  • Astellas Pharma
  • Astellas Pharma Europe B.V.
  • Astellas Pharma Europe BV
  • Dorian Regulatory Affairs BV
  • EMA
  • Erasmus MC
  • Erasmus Medical Center
  • Erasmus Medical Center Rotterdam
  • myTomorrows
  • Pharming Group NV
  • UniQure biopharma B.V.


  • Becton, Dickinson and Company
  • Genzyme Polyclonals
  • Sanofi R&D
  • Sanofi-Aventis R&D
  • Terumo BCT
  • Urgo RID
  • UrgoRID


  • Cytovac
  • Novo Nordisk
  • Novo Nordisk A/S
  • NovoNordisk A/S


  • Boehringer Ingelheim Pharma GmbH & Co.KG
  • CSL Behring GmbH
  • Miltenyi Biotec B.V. & Co. KG


  • CSL Behring AG
  • Sakk
  • University of Zurich


  • Galapagos NV


  • Amniotics AB
  • BioLAmina AB


  • Saudi Food and Drug Authority


  • Hookipa Biotech


  • StemSight


  • Biomarin Pharmaceuticals Inc.


  • Aummune

Saudi Arabia

  • Saudi Food and Drug Authority


  • Educell


  • State Expert Center of Ministry of the Health of Ukraine

Enrol or reserve

Run Pharmaceutical Development of ATMPs Live online for your team

2 days

Typical duration

Pricing from:

  • GBP 800
  • Per attendee, based on 10 attendees
  • Course tailored to your requirements
  • At your choice of location, or online


We can customise this course to your requirements and deliver it on an in-house basis for any number of your staff or colleagues.

Contact our in-house training experts Aleksandra Beer and Yesim Nurko to discuss your requirements:

Multiple colleagues? See above for details of our discounts for 2, 3, or 4 delegates. For more, talk to one of our training experts to discuss how to:

Run this course conveniently and cost-effectively in-house for your staff and colleagues

Aleksandra Beer

Aleksandra BEER
Training expert

Yesim Nurko

Training expert

+44 (0)20 7749 4749